References
- Gehr TW, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999;55:269–77
- McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993;45:232–58
- Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001;141:899–907
- Stoschitzky K, Koshucharova G, Zweiker R, et al. Differing beta-blocking effects of carvedilol and metoprolol. Eur J Heart Fail 2001;3:343–9
- Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994;26:335–46
- Carlson W, Oberg K. Clinical pharmacology of carvedilol. J Cardiovasc Pharmacol Ther 1999;4:205–18
- von Mollendorff E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol 1987;33:511–3
- Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+) and S(–)-carvedilol. Drug Metab Dispos 1997;25:970–7
- Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs 2003;63:1697–741
- Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13
- Taylor RB, Shakoor O, Behrens RH, et al. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 2001;357:1933–6
- European Directorate for the Quality of Medicines. European pharmacopoeia, 5th ed. Strasbourg: 2005 [ISBN 9287152810]
- Therapeutic Goods Administration, 2003. Note for guidance on the investigation of bioavailability and bioequivalence. Available from www.tga.gov.au/docs/pdf/euguide/ewp/140198entga.pdf/ [last accessed: 11 Dec 2005]
- Barone JA. Comparative potency and dissolution performance of internationally available piroxicam products. Pharmaco-economics 1992;1(Suppl. 1):49–52
- Cuenca E, Zaragoza F. Generic drugs in psychopharmacology: pros and cons. Actas Esp Psiquiatr 1999;27:351–7
- Hoag SW, Ramachandruni H, Shangraw RF. Failure of prescription prenatal vitamins products to meet USP standards for folic acid dissolution. J Am Pharm Assoc (Wash) 1997;NS37(4):397–400
- Lambert PA, Conway BR. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J Chemother 2003;15:357–68